These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16787344)

  • 1. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
    Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ
    Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of targeted radiotherapy/gene therapy to bladder cancer cell lines.
    Fullerton NE; Mairs RJ; Kirk D; Keith WN; Carruthers R; McCluskey AG; Brown M; Wilson L; Boyd M
    Eur Urol; 2005 Feb; 47(2):250-6. PubMed ID: 15661422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
    Boyd M; Sorensen A; McCluskey AG; Mairs RJ
    J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.
    Boyd M; Mairs RJ; Keith WN; Ross SC; Welsh P; Akabani G; Owens J; Vaidyanathan G; Carruthers R; Dorrens J; Zalutsky MR
    J Gene Med; 2004 Aug; 6(8):937-47. PubMed ID: 15293352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
    Cunningham SH; Mairs RJ; Wheldon TE; Welsh PC; Vaidyanathan G; Zalutsky MR
    Br J Cancer; 1998 Jun; 77(12):2061-8. PubMed ID: 9649115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill.
    Boyd M; Mairs RJ; Mairs SC; Wilson L; Livingstone A; Cunningham SH; Brown MM; Quigg M; Keith WN
    Oncogene; 2001 Nov; 20(53):7804-8. PubMed ID: 11753659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
    Batra V; Samanta M; Makvandi M; Groff D; Martorano P; Elias J; Ranieri P; Tsang M; Hou C; Li Y; Pawel B; Martinez D; Vaidyanathan G; Carlin S; Pryma DA; Maris JM
    Clin Cancer Res; 2022 Sep; 28(18):4146-4157. PubMed ID: 35861867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate.
    Fullerton NE; Boyd M; Mairs RJ; Keith WN; Alderwish O; Brown MM; Livingstone A; Kirk D
    Prostate Cancer Prostatic Dis; 2004; 7(4):355-63. PubMed ID: 15477875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.
    Boyd M; Ross SC; Dorrens J; Fullerton NE; Tan KW; Zalutsky MR; Mairs RJ
    J Nucl Med; 2006 Jun; 47(6):1007-15. PubMed ID: 16741311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine.
    Boyd M; Cunningham SH; Brown MM; Mairs RJ; Wheldon TE
    Gene Ther; 1999 Jun; 6(6):1147-52. PubMed ID: 10455418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
    Mairs RJ; Ross SC; McCluskey AG; Boyd M
    J Nucl Med; 2007 Sep; 48(9):1519-26. PubMed ID: 17704246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
    Vaidyanathan G; Zhao XG; Larsen RH; Zalutsky MR
    Br J Cancer; 1997; 76(2):226-33. PubMed ID: 9231923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.
    Strickland DK; Vaidyanathan G; Friedman HS; Zalutsky MR
    J Neurooncol; 1995; 25(1):9-17. PubMed ID: 8523094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A gene therapy/targeted radiotherapy strategy for radiation cell kill by.
    Boyd M; Mairs RJ; Cunningham SH; Mairs SC; McCluskey A; Livingstone A; Stevenson K; Brown MM; Wilson L; Carlin S; Wheldon TE
    J Gene Med; 2001; 3(2):165-72. PubMed ID: 11318115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
    Quigg M; Mairs RJ; Brown SM; Harland J; Dunn P; Rampling R; Livingstone A; Wilson L; Boyd M
    Med Chem; 2005 Sep; 1(5):423-9. PubMed ID: 16787326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent.
    Vaidyanathan G; Strickland DK; Zalutsky MR
    Int J Cancer; 1994 Jun; 57(6):908-13. PubMed ID: 8206683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.
    Strickland DK; Vaidyanathan G; Zalutsky MR
    Cancer Res; 1994 Oct; 54(20):5414-9. PubMed ID: 7923174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
    Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
    Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.
    Mairs RJ; Boyd M
    Nucl Med Biol; 2008 Aug; 35 Suppl 1():S9-20. PubMed ID: 18707637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.
    Streby KA; Shah N; Ranalli MA; Kunkler A; Cripe TP
    Pediatr Blood Cancer; 2015 Jan; 62(1):5-11. PubMed ID: 25175627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.